Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations
作者: Kosei HasegawaMasahiro KagabuMika MizunoKatsutoshi OdaDaisuke AokiSeiji MabuchiShoji KamiuraSatoshi YamaguchiYoichi AokiToshiaki SaitoMayu YunokawaKazuhiro TakeharaAikou OkamotoKazunori OchiaiTadashi Kimura
作者单位: 1Saitama Medical University International Medical Center
2Iwate Medical University School of Medicine
3Aichi Cancer Center Hospital
4The University of Tokyo
5Keio University School of Medicine
6Osaka University Graduate School of Medicine
7Osaka International Cancer Center
8Hyogo Cancer Center
9University of the Ryukyus Hospital
10National Kyushu Cancer Center
11National Cancer Center Hospital
12Shikoku Cancer Center
13The Jikei University School of Medicine
刊名: Investigational New Drugs, 2017, Vol.35 (6), pp.800-812
来源数据库: Springer Nature Journal
DOI: 10.1007/s10637-017-0504-6
关键词: PerifosineOvarian cancerEndometrial cancerCervical cancerPIK3CA
英文摘要: Objective Perifosine exhibits anti-tumor activity by inhibiting AKT phosphorylation. The purpose of this phase II basket trial was to evaluate the efficacy and safety of perifosine monotherapy for ovarian, endometrial, and cervical cancers. Methods Recurrent or persistent ovarian, endometrial, or cervical cancer patients were assigned to PIK3CA wild-type or mutant groups. Each patient received 600 mg oral perifosine on day 1 followed by a maintenance dose of 100 mg daily. The primary endpoint was disease control rate; secondary endpoints included response rate, progression-free survival, overall survival, and safety. Immunohistochemical staining and targeted sequencing were used to explore new biomarkers in such patients. Results Sixteen and 5 ovarian, 17 and 7 endometrial, and 18 and 8...
原始语种摘要: Objective Perifosine exhibits anti-tumor activity by inhibiting AKT phosphorylation. The purpose of this phase II basket trial was to evaluate the efficacy and safety of perifosine monotherapy for ovarian, endometrial, and cervical cancers. Methods Recurrent or persistent ovarian, endometrial, or cervical cancer patients were assigned to PIK3CA wild-type or mutant groups. Each patient received 600 mg oral perifosine on day 1 followed by a maintenance dose of 100 mg daily. The primary endpoint was disease control rate; secondary endpoints included response rate, progression-free survival, overall survival, and safety. Immunohistochemical staining and targeted sequencing were used to explore new biomarkers in such patients. Results Sixteen and 5 ovarian, 17 and 7 endometrial, and 18 and 8...
全文获取路径: Springer Nature  (合作)
分享到:
来源刊物:
影响因子:3.498 (2012)

×
关键词翻译
关键词翻译
  • endometrial 子宫内膜的
  • monotherapy 硫化物
  • cervical 颈的
  • gynecologic 妇科学的
  • ovarian 卵巢的
  • recurrent 循环的
  • efficacy 效验
  • survival 生存
  • cancer 癌症
  • basket 篮子